Published in J Biol Chem on February 12, 2010
Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates. J Biol Chem (2012) 0.92
HtrA3 as an early marker for preeclampsia: specific monoclonal antibodies and sensitive high-throughput assays for serum screening. PLoS One (2012) 0.81
HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors. J Cancer (2013) 0.81
Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities. PLoS One (2014) 0.78
Structural and Functional Analysis of Human HtrA3 Protease and Its Subdomains. PLoS One (2015) 0.78
High temperature requirement A3 (HTRA3) expression predicts postoperative recurrence and survival in patients with non-small-cell lung cancer. Oncotarget (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (1988) 14.66
PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization. Trends Biochem Sci (1999) 14.36
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
Translocation of proteins into mitochondria. Annu Rev Biochem (2007) 7.53
The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med (1997) 6.41
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell (2001) 4.24
Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science (1997) 3.94
The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell (2002) 3.77
Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet (1997) 3.11
Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem (2001) 2.71
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem (2001) 2.47
HtrA2 promotes cell death through its serine protease activity and its ability to antagonize inhibitor of apoptosis proteins. J Biol Chem (2001) 2.33
Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene (2003) 2.03
MitoProt, a Macintosh application for studying mitochondrial proteins. Comput Appl Biosci (1995) 2.02
Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet (1997) 2.00
The mitochondrial serine protease HtrA2/Omi: an overview. Cell Death Differ (2008) 1.77
Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. Mol Cell (2004) 1.73
Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev (2003) 1.63
Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem (2002) 1.57
The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ (2002) 1.52
A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene (2004) 1.47
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg (2004) 1.46
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene (2007) 1.36
Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Mol Cell Neurosci (2004) 1.35
Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J Biol Chem (2003) 1.31
Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. Protein Sci (2007) 1.31
Binding of proteins to the PDZ domain regulates proteolytic activity of HtrA1 serine protease. Biochem J (2004) 1.30
HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets (2009) 1.25
The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol (2000) 1.24
Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res (2008) 1.22
S-peptide epitope tagging for protein purification, expression monitoring, and localization in mammalian cells. Biotechniques (2004) 1.21
Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) (2008) 1.20
Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci (1996) 1.19
Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ (2004) 1.15
Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol (2009) 1.12
Naked2 acts as a cargo recognition and targeting protein to ensure proper delivery and fusion of TGF-alpha containing exocytic vesicles at the lower lateral membrane of polarized MDCK cells. Mol Biol Cell (2007) 1.10
Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. Mol Cell Neurosci (2005) 1.10
Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol (2006) 1.10
Apoptosis in the treatment of cancer: a promise kept? Curr Opin Cell Biol (2006) 1.02
Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am J Respir Cell Mol Biol (2008) 1.01
Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene (2007) 0.98
Autocatalytic processing of HtrA2/Omi is essential for induction of caspase-dependent cell death through antagonizing XIAP. J Biol Chem (2004) 0.97
Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem (2009) 0.96
Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials (2008) 0.94
Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol (2004) 0.93
The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function. Cell Death Differ (2002) 0.92
Advances in the biology of lung cancer chemoprevention. J Clin Oncol (2005) 0.92
UCP-2 and UCP-3 proteins are differentially regulated in pancreatic beta-cells. PLoS One (2008) 0.88
Modern management of small-cell lung cancer. Drugs (2007) 0.88
Management of small cell lung cancer. Curr Treat Options Oncol (2006) 0.83
Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. Clin Lung Cancer (2004) 0.80
Expression of Brachyury in mesenchymal progenitor cells leads to cartilage-like tissue that is resistant to the destructive effect of rheumatoid arthritis synovial fibroblasts. J Tissue Eng Regen Med (2009) 0.79
Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin (2008) 0.76
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science (2006) 5.67
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 2.40
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J Clin Invest (2008) 2.24
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (2011) 2.00
hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology (2004) 1.95
HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene (2004) 1.82
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol (2009) 1.82
Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer (2012) 1.78
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res (2006) 1.71
MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci (2003) 1.54
AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model. Nutr Metab (Lond) (2006) 1.49
Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A (2005) 1.47
A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene (2004) 1.47
Early detection of ovarian cancer: promise and reality. Cancer Treat Res (2002) 1.45
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. Bioinformatics (2011) 1.41
Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem (2007) 1.39
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Role of hedgehog signaling in ovarian cancer. Clin Cancer Res (2008) 1.36
Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. PLoS Comput Biol (2013) 1.34
Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res (2002) 1.29
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology (2006) 1.27
HtrA serine proteases as potential therapeutic targets in cancer. Curr Cancer Drug Targets (2009) 1.25
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene (2005) 1.24
Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol (2005) 1.24
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma. Pharmacogenomics (2008) 1.15
Heterozygous ATR mutations in mismatch repair-deficient cancer cells have functional significance. Cancer Res (2005) 1.14
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol (2009) 1.12
Highly parallel genome-wide expression analysis of single mammalian cells. PLoS One (2012) 1.10
Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res (2010) 1.10
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 1.09
Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem (2007) 1.09
Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer (2004) 1.05
Pattern of expression of HtrA1 during mouse development. J Histochem Cytochem (2004) 1.02
Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J (2002) 1.02
Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol (2013) 1.02
Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion. Am J Obstet Gynecol (2008) 0.99
Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res (2009) 0.98
DIXDC1 isoform, l-DIXDC1, is a novel filamentous actin-binding protein. Biochem Biophys Res Commun (2006) 0.98
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. Hum Mol Genet (2013) 0.97
Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. PLoS One (2013) 0.96
Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem (2009) 0.96
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer (2012) 0.95
Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun (2009) 0.95
Role of heparan sulfatases in ovarian and breast cancer. Am J Cancer Res (2013) 0.95
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene (2003) 0.94
Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. Breast Cancer Res (2012) 0.94
Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res (2010) 0.93
Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol (2010) 0.92
Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol (2009) 0.92
The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein. Mol Cancer Res (2010) 0.90
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res (2006) 0.88
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol (2012) 0.87
Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res (2004) 0.86
Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. Cancer Res (2006) 0.86
Discovery and validation of methylation markers for endometrial cancer. Int J Cancer (2014) 0.86
Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics (2014) 0.86
Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol Carcinog (2011) 0.85
Comparison of gene expression patterns between avian and human ovarian cancers. Gynecol Oncol (2010) 0.84
HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. Int J Cancer (2011) 0.84
Expression and functional significance of HtrA1 loss in endometrial cancer. Clin Cancer Res (2010) 0.83
Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. Int J Cancer (2014) 0.82
HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer. Histopathology (2011) 0.82
Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts. Clin Exp Metastasis (2013) 0.79
High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res (2014) 0.78
Challenges and opportunities for next-generation sequencing in companion diagnostics. Expert Rev Mol Diagn (2014) 0.76
Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics (2014) 0.75
Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle (2012) 0.75
Assessment of resistance to anoikis in ovarian cancer. Methods Mol Biol (2013) 0.75